Completed PHASE1 INTERVENTIONAL 2-arm NCT00868660

Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose

A Phase I, Double Blind, Placebo-Controlled Study of ZP1848 Administered as Subcutaneous Bolus Injections in Healthy Subjects Followed by Multiple Doses in Patients With Crohn's Disease in Remission

Sponsor: Zealand Pharma

Conditions Inflammatory Bowel Disease

Interventions ZP1848

Updated 6 times since 2017 Last updated: Nov 1, 2010 Started: Jan 31, 2009 Primary completion: Feb 28, 2010 Completion: Feb 28, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Inflammatory Bowel Disease, this trial is completed. The trial is conducted by Zealand Pharma and has accumulated 6 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Zealand Pharma

Data source: Zealand Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Willingboro, United States